乌帕替尼临床试验项目中类风湿关节炎、银屑病关节炎和强直性脊柱炎的主要不良心血管事件与静脉血栓栓塞事件
该研究整合分析了乌帕替尼15 mg与30 mg每日一次治疗类风湿关节炎、银屑病关节炎和强直性脊柱炎的2b/3期临床试验数据,共4298例接受15 mg和2125例接受30 mg。类风湿关节炎和银屑病关节炎中主要不良心血管事件率为0.3-0.6事件/100患者年,静脉血栓栓塞事件率为0.2-0.4事件/100患者年,两剂量相似;强直性脊柱炎无主要不良心血管事件、发生1例静脉血栓栓塞事件。结论认为乌帕替尼的事件率与既往传统合成及生物改善病情抗风湿药数据一致,与阿达木单抗和甲氨蝶呤相当。
要点
- 类风湿关节炎和银屑病关节炎中主要不良心血管事件率0.3-0.6事件/100患者年,静脉血栓栓塞事件率0.2-0.4事件/100患者年,两剂量相似。
- 强直性脊柱炎患者无主要不良心血管事件,发生1例静脉血栓栓塞事件。
- 发生主要不良心血管事件或静脉血栓栓塞事件的大多数患者有2个或以上基线心血管危险因素。
核心结论
- 乌帕替尼治疗的主要不良心血管事件和静脉血栓栓塞事件率与既往报道的传统合成及生物改善病情抗风湿药数据一致,与活性对照药阿达木单抗和甲氨蝶呤相当。
- 相关患者特征为主要不良心血管事件和静脉血栓栓塞事件的已知危险因素。
研究设计与样本
- 整合分析类风湿关节炎、银屑病关节炎和强直性脊柱炎的2b/3期乌帕替尼临床试验项目数据(截至2021年6月30日)。
- 4298例患者接受乌帕替尼15 mg每日一次(类风湿关节炎n=3209、银屑病关节炎n=907、强直性脊柱炎n=182)。
- 2125例患者接受乌帕替尼30 mg每日一次(类风湿关节炎n=1204、银屑病关节炎n=921)。
- 对照臂包括阿达木单抗(类风湿关节炎和银屑病关节炎)和甲氨蝶呤(类风湿关节炎)。
- 主要不良心血管事件和静脉血栓栓塞事件经判定后以每100患者年的暴露校正率(E/100 PY)表示,采用单变量Cox比例风险回归分析危险因素关联。
主要发现
- 类风湿关节炎和银屑病关节炎患者中,主要不良心血管事件率为0.3-0.6事件/100患者年,静脉血栓栓塞事件率为0.2-0.4事件/100患者年,乌帕替尼两剂量间相似。
- 强直性脊柱炎患者中无主要不良心血管事件发生,发生1例静脉血栓栓塞事件。
- 发生主要不良心血管事件或静脉血栓栓塞事件的大多数患者有2个或以上基线心血管危险因素。
- 类风湿关节炎和银屑病关节炎组间主要不良心血管事件率和静脉血栓栓塞事件率相似。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To provide an integrated analysis of major adverse cardiovascular events (MACEs) and events of venous thromboembolism (VTE) and associated risk factors across rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) phase 2b/3 upadacitinib clinical programmes. METHODS: Data were analysed and summarised from clinical trials of RA, PsA and AS treated with upadacitinib 15 mg once daily (QD) and 30 mg QD (as of 30 June 2021). Data from adalimumab (RA and PsA) and methotrexate (RA) arms were included as comparators. Adjudicated MACEs and VTE events were presented as exposure-adjusted rates per 100 patient-years (E/100 PY). Univariable Cox proportional hazard regression analyses assessed potential associations of risk factors for MACE and VTE. RESULTS: In total, 4298 patients received upadacitinib 15 mg (RA n=3209, PsA n=907 and AS n=182) and 2125 patients received upadacitinib 30 mg (RA n=1204 and PsA n=921). In patients with RA and PsA, rates of MACE (0.3-0.6 E/100 PY) and VTE (0.2-0.4 E/100 PY) were similar across upadacitinib doses; in patients with AS, no MACEs and one VTE event occurred. Most patients experiencing MACEs or VTE events had two or more baseline cardiovascular risk factors. Across RA and PsA groups, rates of MACEs and VTE events were similar. CONCLUSIONS: Rates of MACEs and VTE events with upadacitinib were consistent with previously reported data for patients receiving conventional synthetic and biologic disease-modifying anti-rheumatic drugs and comparable with active comparators adalimumab and methotrexate. Associated patient characteristics are known risk factors for MACEs and VTE events. TRIAL REGISTRATION NUMBERS: RA (SELECT-NEXT: NCT02675426; SELECT-MONOTHERAPY: NCT02706951; SELECT-BEYOND: NCT02706847; SELECT-COMPARE: NCT02629159; SELECT-EARLY: NCT02706873, SELECT-CHOICE: NCT03086343), PsA (SELECT-PsA 2: NCT03104374; SELECT-PsA 1: NCT03104400), and AS (SELECT-AXIS 1: NCT03178487).
引用
- Charles-Schoeman C, Choy E, McInnes IB, et al. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open. 2023. PMID: 37945286. doi:10.1136/rmdopen-2023-003392
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。